Published in Cancer Res on May 01, 2008
Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov (2012) 3.88
c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J (2010) 2.33
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet (2014) 2.11
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst (2012) 2.01
The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. Cancer Discov (2014) 1.38
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem (2012) 1.27
Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma. Oncogene (2009) 1.09
The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. Arch Biochem Biophys (2014) 1.05
A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A (2009) 1.04
MITF-siRNA formulation is a safe and effective therapy for human melasma. Mol Ther (2010) 1.01
MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol (2015) 0.91
Pro-survival role of MITF in melanoma. J Invest Dermatol (2014) 0.91
C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS One (2011) 0.88
TFEB at a glance. J Cell Sci (2016) 0.87
BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene. Pigment Cell Melanoma Res (2013) 0.86
Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. Cancer Immunol Immunother (2011) 0.86
Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo) (2013) 0.85
Skeletal muscle phenotypically converts and selectively inhibits metastatic cells in mice. PLoS One (2010) 0.84
Novel primate-specific genes, RMEL 1, 2 and 3, with highly restricted expression in melanoma, assessed by new data mining tool. PLoS One (2010) 0.81
MITF-independent pro-survival role of BRG1-containing SWI/SNF complex in melanoma cells. PLoS One (2013) 0.81
Alteration of TEAD1 expression levels confers apoptotic resistance through the transcriptional up-regulation of Livin. PLoS One (2012) 0.81
SWI/SNF chromatin remodeling enzymes in melanocyte differentiation and melanoma. Crit Rev Eukaryot Gene Expr (2014) 0.80
MiTF links Erk1/2 kinase and p21 CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cells. Mol Cancer (2010) 0.80
Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res (2015) 0.79
Role of melanoma inhibitor of apoptosis (ML-IAP) protein, a member of the baculoviral IAP repeat (BIR) domain family, in the regulation of C-RAF kinase and cell migration. J Biol Chem (2012) 0.79
Endothelin-1 enhances the melanogenesis via MITF-GPNMB pathway. BMB Rep (2013) 0.78
New Perspectives of "omics" Applications in Melanoma Research. Open Biochem J (2011) 0.77
SWItching on the transcriptional circuitry in melanoma. Epigenetics (2010) 0.76
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis. Cancer Biol Ther (2016) 0.75
BPTF transduces MITF-driven prosurvival signals in melanoma cells. Proc Natl Acad Sci U S A (2016) 0.75
MicroRNA-3196 is inhibited by H2AX phosphorylation and attenuates lung cancer cell apoptosis by downregulating PUMA. Oncotarget (2016) 0.75
The functional property of royal jelly 10-hydroxy-2-decenoic acid as a melanogenesis inhibitor. BMC Complement Altern Med (2017) 0.75
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature (2004) 14.80
The PredictProtein server. Nucleic Acids Res (2004) 10.89
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med (2013) 8.89
Non-canonical inflammasome activation targets caspase-11. Nature (2011) 8.85
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell (2007) 8.48
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
The genome of M. acetivorans reveals extensive metabolic and physiological diversity. Genome Res (2002) 4.58
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature (2009) 4.12
Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov (2012) 3.88
c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem (2008) 3.54
Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res (2006) 3.12
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res (2006) 2.84
The PredictProtein server. Nucleic Acids Res (2003) 2.72
Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature (2006) 2.69
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69
Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 2.54
The mitochondrial inner membrane protein mitofilin controls cristae morphology. Mol Biol Cell (2005) 2.53
USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell (2011) 2.51
Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J Biol Chem (2001) 2.45
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res (2008) 2.33
c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J (2010) 2.33
The protein target list of the Northeast Structural Genomics Consortium. Proteins (2004) 2.31
Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol (2009) 2.26
Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science (2014) 2.23
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov (2011) 2.22
The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res (2012) 2.19
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol (2006) 1.97
Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). Biochem J (2009) 1.94
Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and promote S phase entry. Mol Cell (2011) 1.92
Phosphorylation of NLRC4 is critical for inflammasome activation. Nature (2012) 1.92
Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem (2005) 1.87
Predicting transmembrane beta-barrels in proteomes. Nucleic Acids Res (2004) 1.83
COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature (2011) 1.83
Effects of permissive hypercapnia on transient global cerebral ischemia-reperfusion injury in rats. Anesthesiology (2010) 1.78
Understanding the physical properties that control protein crystallization by analysis of large-scale experimental data. Nat Biotechnol (2009) 1.78
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med (2013) 1.71
Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol (2013) 1.68
The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res (2007) 1.63
Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem Biol (2009) 1.60
Novel leverage of structural genomics. Nat Biotechnol (2007) 1.57
Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol (2005) 1.54
Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci U S A (2007) 1.54
Structural genomics is the largest contributor of novel structural leverage. J Struct Funct Genomics (2009) 1.52
Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity. ACS Chem Biol (2012) 1.50
PPM1H is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discov (2011) 1.50
Improved quantitative mass spectrometry methods for characterizing complex ubiquitin signals. Mol Cell Proteomics (2010) 1.43
PEP: Predictions for Entire Proteomes. Nucleic Acids Res (2003) 1.39
Cellular inhibitors of apoptosis are global regulators of NF-κB and MAPK activation by members of the TNF family of receptors. Sci Signal (2012) 1.39
(Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle (2008) 1.36
Uniform nomenclature for the mitochondrial contact site and cristae organizing system. J Cell Biol (2014) 1.34
Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science (2011) 1.32
The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2. J Biol Chem (2006) 1.32
Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J (2005) 1.31
Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis. Differentiation (2006) 1.29
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem (2012) 1.27
Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure (2009) 1.24
An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res (2012) 1.23
Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res (2011) 1.23
A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell (2013) 1.22
Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Mol Cancer Ther (2012) 1.20
Comparisons of NMR spectral quality and success in crystallization demonstrate that NMR and X-ray crystallography are complementary methods for small protein structure determination. J Am Chem Soc (2005) 1.19
Natively unstructured loops differ from other loops. PLoS Comput Biol (2007) 1.19
Membrane protein prediction methods. Methods (2007) 1.17
SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J Biol Chem (2002) 1.17
Exploring protein-protein interactions with phage display. Chembiochem (2003) 1.17
Small-molecule pan-IAP antagonists: a patent review. Expert Opin Ther Pat (2010) 1.14
Identification of a novel death domain-containing adaptor molecule for ectodysplasin-A receptor that is mutated in crinkled mice. Curr Biol (2002) 1.14
Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry (2003) 1.09
OTUB1 modulates c-IAP1 stability to regulate signalling pathways. EMBO J (2013) 1.09
The double-histone-acetyltransferase complex ATAC is essential for mammalian development. Mol Cell Biol (2008) 1.09
BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site. Biochemistry (2003) 1.08
X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem (2009) 1.08
Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis. Neoplasia (2011) 1.08
FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth. Cancer Res (2012) 1.05
Phosphorylation of a borealin dimerization domain is required for proper chromosome segregation. Biochemistry (2009) 1.03
Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. Mol Cancer Ther (2013) 1.03
Antagonists of IAP proteins as cancer therapeutics. Cancer Lett (2010) 1.03
Inferring disease and gene set associations with rank coherence in networks. Bioinformatics (2011) 1.01
Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor. J Mol Biol (2002) 1.00
Diverse modes of genomic alteration in hepatocellular carcinoma. Genome Biol (2014) 0.99
Phosphoproteome analysis of the human Chang liver cells using SCX and a complementary mass spectrometric strategy. Proteomics (2008) 0.99
Conformational dynamics control ubiquitin-deubiquitinase interactions and influence in vivo signaling. Proc Natl Acad Sci U S A (2013) 0.99